Eloralintide vs Tirzepatide
Eloralintide (LY3841136) and Tirzepatide (LY3298176) both target completely different receptor systems: Eloralintide is a selective amylin receptor agonist, Tirzepatide is a dual GLP-1/GIP agonist. They are not competitors: Lilly is developing them together, and a 48-week Phase 2b of the combination reported in September 2026. This page compares each as a research compound.
Eloralintide 10mg is booked in for a full-panel independent test at Vanguard Laboratory: purity, quantity, endotoxins and sterility. Results from late October, in the COA Library.
| Eloralintide | Tirzepatide | |
|---|---|---|
| Development code | LY3841136 | LY3298176 |
| Receptor targets | Amylin receptors (selective) | GLP-1 + GIP receptors (dual) |
| Mechanism family | Amylin analogue | Incretin analogue |
| Approval status | Investigational, Phase 3 | Approved prescription medicine |
| Administration frequency | Once weekly | Once weekly |
| Combination role | Amylin partner in the combination | Incretin backbone, standalone or combo |
| Phase 2b, 48 weeks, type 2 diabetes | With Tirzepatide: up to 23.3% | Alone: 14.8% |
| Peptx availability | Factory Direct kits; UK single vials on waitlist |
- Development code
- LY3841136LY3298176
- Receptor targets
- Amylin receptors (selective)GLP-1 + GIP receptors (dual)
- Mechanism family
- Amylin analogueIncretin analogue
- Approval status
- Investigational, Phase 3Approved prescription medicine
- Administration frequency
- Once weeklyOnce weekly
- Combination role
- Amylin partner in the combinationIncretin backbone, standalone or combo
- Phase 2b, 48 weeks, type 2 diabetes
- With Tirzepatide: up to 23.3%Alone: 14.8%
- Peptx availability
Different receptor systems, complementary pharmacology
Tirzepatide activates the GLP-1 and GIP incretin receptors: the pathway that dominated obesity pharmacology from 2019 onwards. GLP-1 drives glucose-dependent insulin release, glucagon suppression, and central satiety; GIP adds insulin-sensitivity and lipid-handling effects.
Eloralintide activates the amylin receptor system, a completely separate axis. Amylin signalling operates principally on hypothalamic and area postrema satiety circuits, gastric emptying, and postprandial glucagon suppression. The combination therefore hits appetite via two mechanistically independent pathways at once.
Why the combination is interesting
Tirzepatide monotherapy in SURMOUNT-1 produced 22.5% mean body-weight reduction at 72 weeks at the 15mg dose, the current pharmacological ceiling for a licensed medication. Retatrutide phase 2 extended that to 24% via a third receptor (glucagon).
Eloralintide plus Tirzepatide takes a different route: keep the dual incretin backbone and add a selective amylin agonist on top. In a 48-week Phase 2b trial in 367 adults with obesity or overweight and type 2 diabetes, presented at EASD on 30 September 2026, the highest-dose combination reached 23.3% mean weight reduction against 14.8% with Tirzepatide alone, and HbA1c fell by up to 2.9% against 2.4%. Gastrointestinal effects were mostly mild or moderate and came mainly during dose escalation. Lilly has said Phase 3 trials of the combination start in the fourth quarter of 2026.
Bottom line for research labs
These are complementary, not competing, compounds. Tirzepatide is the mature reference incretin peptide with the deeper published literature. Eloralintide is the novel amylin arm of what will likely become the next-generation combination therapy. A research lab studying obesity pharmacology today typically wants access to both.